Ország: Egyesült Királyság
Nyelv: angol
Forrás: MHRA (Medicines & Healthcare Products Regulatory Agency)
Adenosine
Wockhardt UK Ltd
C01EB10
Adenosine
3mg/1ml
Solution for infusion
Intravenous
No Controlled Drug Status
Valid as a prescribable product
BNF: 02030200; GTIN: 5012727907383
8 CUSTOMER PRODUCT NAME ITEM CODE OUR REF DATE PREVIOUS VERSION PHARMACODE NO MATERIAL FLAT SIZE FOLD SIZE VIEW PANEL FOLD DETAIL PACKING DETAILS COLOURS FRONT COLOURS BACK CUSTOMER PRODUCT NAME ITEM CODE OUR REF PROOF NO DATE PREVIOUS VERSION PHARMACODE NO MATERIAL FLAT SIZE FOLD SIZE VIEW PANEL FOLD DETAIL PACKING DETAILS COLOURS FRONT COLOURS BACK CP Pharmaceuticals Limited ADENOSINE 30MG/10ML SOLUTION FOR INFUSION 105569/3-S2S SO44387 One 10/04/2015 105569/2-S2S Supplied 50gsm Opaque 300 x 148 148 x 27/25 PHARMACODE TO VIEW PARALLEL Shrinkwrapped in trays BLACK BLACK 8 CUSTOMER PRODUCT NAME ITEM CODE OUR REF DATE PREVIOUS VERSION PHARMACODE NO MATERIAL FLAT SIZE FOLD SIZE VIEW PANEL FOLD DETAIL PACKING DETAILS COLOURS FRONT COLOURS BACK SO44387_105569/3-S2S_P1.indd 1 10/04/2015 15:35 SO44387_105569/3-S2S_P1.indd 2 10/04/2015 15:35 Olvassa el a teljes dokumentumot
OBJECT 1 ADENOSINE 30MG/10ML SOLUTION FOR INFUSION Summary of Product Characteristics Updated 10-Jun-2015 | Wockhardt UK Ltd 1. Name of the medicinal product Adenosine 30mg/10ml Solution for Infusion 2. Qualitative and quantitative composition Each vial contains 30mg of adenosine per 10ml (3mg/ml). Excipient: each vial contains approximately 36 mg of sodium per vial (10ml). For a full list of excipients, see Section 6.1. 3. Pharmaceutical form Solution for infusion. A clear, colourless solution free from visible particles. 4. Clinical particulars 4.1 Therapeutic indications Intravenous (IV) adenosine infusion is a coronary vasodilator for use in conjunction with radionuclide myocardial perfusion imaging in patients who cannot exercise adequately or for whom exercise is inappropriate. 4.2 Posology and method of administration Adenosine infusion is intended for use in hospitals with monitoring and cardio-respiratory resuscitation equipment available for immediate use if necessary. It should be administered following the same procedure as for exercise testing where facilities for cardiac monitoring and cardio-respiratory resuscitation are available. During administration of adenosine infusion continuous ECG control is necessary as life-threatening arrhythmia might occur. Heart rate and blood pressure should be monitored every minute. ADULTS: 1. Adenosine infusion should be administered undiluted as a continuous peripheral intravenous infusion at a dose of 140 µg/kg/min for six minutes using an infusion pump. Separate venous sites for adenosine infusion and radionuclide administration are recommended to avoid an adenosine bolus effect. 2. After three minutes of adenosine infusion, the radionuclide is injected to ensure sufficient time for peak coronary blood flow to occur. The optimal vasodilator protocol is achieved with six minutes of adenosine infusion. 3. To avoid an adenosine bolus effect, blood pressure should be measured in the arm opposite to the adenosine infusion. The table below is given as a guide for ad Olvassa el a teljes dokumentumot